Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Rivaroxaban × Plasma cell × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Genitourinary 1 Classical hematology 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 8 daratumumab 5 Lenalidomide 5 Bortezomib 5 Trimethoprim, Sulfamethoxazole Drug Combination 4 Thalidomide 4 Cyclophosphamide 4 gamma-Globulins 3 Ciprofloxacin 3 carfilzomib 2 Melphalan 2 Immunoglobulins, Intravenous 2 Calcium Dobesilate 2 Amoxicillin-Potassium Clavulanate Combination 2 trametinib 1 tanespimycin 1 pomalidomide 1 pazopanib 1 fludarabine 1 dabrafenib 1 cobimetinib 1 Whole-Body Irradiation 1 Vemurafenib 1 Stem Cell Transplantation 1 Rivaroxaban 1 Radiotherapy 1 Radiation 1 Pharmaceutical Preparations 1 Mesna 1 MAGEA3 protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03428373 2024-02-29

RithMM

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2/3 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡